-- 5N Plus (VNP.TO) 周三盘后公布，其第一季度利润和营收均同比增长。 该公司当季盈利1780万美元，合每股0.20美元，高于去年同期的960万美元，合每股0.11美元。FactSet此前预期每股收益为0.14美元。 营收从去年同期的8890万美元增至1.179亿美元。FactSet此前预期为1.04亿美元。该公司表示，营收增长主要得益于特种半导体业务销量增加以及高性能材料业务中铋基产品价格上涨。 该公司补充道，维持其2026年调整后EBITDA预期区间在1亿美元至1.05亿美元之间。 “2026年，5N+预计特种半导体市场需求将保持强劲，这得益于其核心终端市场的结构性扩张，尤其是在陆地可再生能源和太空太阳能等战略领域。这些趋势，加上公司作为中国以外全球领先的超高纯度特种半导体化合物供应商的地位，预计将继续支撑该领域的长期增长。”5N+表示。 该公司股票在多伦多证券交易所收盘上涨0.85美元，至36.05美元。
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661